SciClone Appoints PricewaterhouseCoopers LLP as Its Independent Registered Public Accounting Firm

SciClone Appoints PricewaterhouseCoopers LLP as Its Independent Registered 
Public Accounting Firm 
FOSTER CITY, CA -- (Marketwired) -- 04/08/13 --  SciClone
Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the Audit
Committee of the Company's Board of Directors has appointed
PricewaterhouseCoopers LLP ("PwC") as its independent registered
public accounting firm, effective immediately, to perform independent
audit services beginning with the fiscal year ending December 31,
2013. PwC is a global network of firms that specializes in audit and
assurance, tax and consulting services. The PwC network spans more
than 150 countries and the firm has a long history of providing these
solutions to clients in the pharmaceutical and life sciences
industries around the globe, including the Chinese market.  
"PwC is well respected for its expertise and experience in the global
pharmaceutical industry, and especially for its deep knowledge of the
China pharmaceuticals market and strong reputation for working
effectively with companies in the US and in China to meet the
challenges and opportunities of a complex and changing business
environment," said Gary S. Titus, SciClone Chief Financial Officer.
"We are extremely pleased to welcome PwC as SciClone's new
independent auditor, and lo
ok forward to establishing a collaborative
and productive relationship over many years." 
As in the last several years, SciClone will continue to also work
with another global, Big Four firm regarding non-audit work, such as
internal controls and tax advisory matters in the US, China and other
parts of the world where the Company has operations. 
About SciClone  
SciClone Pharmaceuticals is a US-based, China-focused specialty
pharmaceutical company with a product portfolio of therapies for
oncology, infectious diseases and cardiovascular, urological,
respiratory, and central nervous system disorders. SciClone's
ZADAXIN(R) (thymalfasin) is approved in over 30 countries and may be
used for the treatment of hepatitis B (HBV), hepatitis C (HCV) and
certain cancers, and as a vaccine adjuvant, according to the local
regulatory approvals. Besides ZADAXIN, SciClone markets about 14
mostly partnered products in China, including Depakine(R), the most
widely prescribed broad-spectrum anti-convulsant in China;
Tritace(R), an ACE inhibitor for the treatment of hypertension;
Stilnox(R), a leading hypnotic for the short-term treatment of
insomnia (marketed as Ambien(R) in the US); and Aggrastat(R), a
recently-launched interventional cardiology product. SciClone is also
pursuing the registration of several other therapeutic products in
China. SciClone is headquartered in Foster City, California. For
additional information, please visit www.sciclone.com.  
Forward-Looking Statements 
This press release contains forward-looking statements regarding
expected financial results and expectations. Readers are urged to
consider statements that include the words "may," "will," "would,"
"could," "should," "might," "believes," "estimates," "projects,"
"potential," "expects," "plans," "anticipates," "intends,"
"continues," "forecast," "designed," "goal," "unaudited,"
"approximately" or the negative of those words or other comparable
words to be uncertain and forward-looking. These statements are
subject to risks and uncertainties that are difficult to predict and
actual outcomes may differ materially. Please also refer to other
risks and uncertainties described in SciClone's filings with the SEC.
All forward-looking statements are based on information currently
available to SciClone and SciClone assumes no obligation to update
any such forward-looking statements. 
Ambien, Depakine, Stilnox and Tritace are registered trademarks of
Sanofi and/or its affiliates. 
Aggrastat is a registered trademark of Medicure International Inc. in
the United States, and Iroko Cardio LLC in numerous other countries. 
SciClone, SciClone Pharmaceuticals, the SciClone Pharmaceuticals
design, the SciClone logo and ZADAXIN are registered trademarks of
SciClone Pharmaceuticals, Inc. in the United States and numerous
other countries. 
Corporate Contacts 
Gary Titus
Chief Financial Officer
650.358.3456
gtitus@sciclone.com 
Jane Green 
Investors/Media
650.358.1447
jgreen@sciclone.com